NCT05675462View on ClinicalTrials.gov

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Oncorine

a modified human recombinant type 5 adenovirus with genetic modifications

DRUG

Tislelizumab

PD-1inhibitor

DRUG

Lenvatinib

TKI

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER